Olaris, Inc. Announces Presentation on Metabolic Biomarkers of Response in Advanced GIST at American Association for Cancer Research (AACR) 2021 Annual Meeting
Share Article
Olaris to present new data on metabolic signatures predictive of overall survival and therapeutic response in advanced GIST at upcoming AACR Virtual Meeting
This study is particularly exciting as we were able to demonstrate and validate in an independent set of patient samples that metabolite biomarkers either before treatment or during treatment can identify patients with favorable clinical outcomes.” - Dr. Elizabeth O’Day, CEO and Founder of Olaris WALTHAM, Mass. (PRWEB) April 09, 2021 Olaris, Inc, a precision medicine company leveraging metabolomics and machine learning for the discovery and development of Biomarkers of Response (BoRs) to optimize treatments and patient outcomes, is pleased to announce the company’s presentation on
Surface Oncology Presents Promising Preclinical Data for Lead Immunotherapy Product Candidates at the American Association for Cancer Research Annual Meeting
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
Rubius Therapeutics Presents Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
CHOP Cancer Researchers Win 2021 AACR Team Science Award
April 9, 2021 GMT
John M. Maris, MD
PHILADELPHIA, April 9, 2021 /PRNewswire/ Twelve researchers in the Cancer Center at Children’s Hospital of Philadelphia (CHOP) have won the 2021 Team Science Award from the American Association for Cancer Research (AACR). The award, presented annually at the AACR Annual Meeting for collaborative scientific advancements, recognizes the significant contributions to the pediatric cancer research community made by the St. Baldrick’s Foundation-Stand Up 2 Cancer Pediatric Dream Team. The Team is led by CHOP physician-scientist John M. Maris, MD and co-leader Stanford University immunologist and pediatric oncologist Crystal L. Mackall, MD, and supported by a multi-disciplinary group of researchers across 10 North American centers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Affimed Announces Presentation at AACR Highlighting Initial Data from Phase 1 Study of Cord .
Affimed N.V.April 9, 2021 GMT
All four patients experienced significant disease reduction, with two complete responses and two partial responses as assessed by the investigator, with an objective response rate of 100%
There were no observed events of cytokine release syndrome, neurotoxicity syndrome or graft-versus-host disease
Study is continuing enrollment of the second dose cohort
Company to host conference call/webcast on April 14 at 4:05 p.m. EDT
ADVERTISEMENT
Heidelberg, Germany, April 9, 2021
– Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today positive initial clinical data from an investigator-sponsored study at The University of Texas MD Anderson Cancer Center evalu